Abstract
Background
Statin therapy used to lower cholesterol levels results in a substantial reduction in cardiovascular complications. Previous observations in different ethnic populations showed that rs2306283A>G, p.Asn130Asp and rs4149056T>C, p.Val174Ala in solute carrier organic anion transporter 1B1 (SLCO1B1) gene encoding the organic transporter protein may be responsible for statin uptake, thus explaining the majority of statin-associated symptoms. In addition to the genetic component, vitamin D (vit D) deficiency is common in Saudi Arabia and worldwide and may cause muscle dysfunction and ache. The aim of the present study was first to reveal an effect of vit D, rs2306283A>G, and rs4149056T>C and related haplotypes on statin-associated myopathy (SAM) and then to investigate a possible interaction between low vit D levels and the above-mentioned variants.
Methods
The genomic DNA obtained from 50 individuals diagnosed with hypercholesterolemia was genotyped using light SNiP hybridization probes.
Results
Low vit D levels were associated with SAM (OR=3.6, p=0.03); however, CK levels, rs2306283A>G, and rs4149056T>C did not show any association. Interestingly, rs4149056T>C was interacting with vit D to influence SAM (p=0.02). Haplotype analysis showed that SLCO1B1 *1B and *15 were more prevalent in individuals with SAM (p=0.05). When stratified according to vit D levels, rs2306283A allele showed an increase in individuals having SAM along with low vit D (p=0.03).
Conclusions
Although preliminary, our results show an involvement of vit D and rs4149056T>C of SLCO1B1 in SAM.
Acknowledgments
The authors would like to thank the study participants.
Author contributions: All the authors have accepted responsibility for the entire content of the submitted manuscript and approved submission.
Research funding: The present work was funded by an internal research grant (project number 0712017) from AlFaisal University, Ryadh, Kingdom of Saudi Arabia.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. WHO. Cardiovascular diseases (CVDs). WHO fact sheet, 2017.Search in Google Scholar
2. Mikhailidis DP, Athyros VG. Dyslipidaemia in 2013: new statin guidelines and promising novel therapeutics. Nat Rev Cardiol 2014;11:72–4.10.1038/nrcardio.2013.209Search in Google Scholar PubMed
3. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel statement on assessment, aetiology and management. Eur Heart J 2015;36:1012–22.10.1093/eurheartj/ehv043Search in Google Scholar PubMed PubMed Central
4. Vrablik M, Zlatohlavek L, Stulc T, Adamkova V, Prusikova M, Schwarzova L, et al. Statin-associated myopathy: from genetic predisposition to clinical management. Physiol Res 2014;63:S327–34.10.33549/physiolres.932865Search in Google Scholar PubMed
5. Jacobs ET, Alberts DS, Foote JA, Green SB, Hollis BW, Yu Z, et al. Vitamin D insufficiency in southern Arizona. Am J Clin Nutr 2008;87:608–13.10.1093/ajcn/87.3.608Search in Google Scholar PubMed PubMed Central
6. Goldstein MR. Myopathy, statins, and vitamin D deficiency. Am J Cardiol 2007;100:1328.10.1016/j.amjcard.2007.05.017Search in Google Scholar PubMed
7. Prabhala A, Garg R, Dandona P. Severe myopathy associated with vitamin D deficiency in western New York. Arch Intern Med 2000;160:1199–203.10.1001/archinte.160.8.1199Search in Google Scholar PubMed
8. Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 2007; 18:401–8.10.1097/MOL.0b013e32825a6773Search in Google Scholar PubMed
9. Ahmed W, Khan N, Glueck CJ, Pandey S, Wang P, Goldenberg N, et al. Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res 2009;153:11–6.10.1016/j.trsl.2008.11.002Search in Google Scholar PubMed
10. Morioka TY, Lee AJ, Bertisch S, Buettner C. Vitamin D status modifies the association between statin use and musculoskeletal pain: a population based study. Atherosclerosis 2015;238:77–82.10.1016/j.atherosclerosis.2014.11.012Search in Google Scholar PubMed PubMed Central
11. Lee P, Greenfield JR, Campbell LV. Vitamin D insufficiency – a novel mechanism of statin-induced myalgia? Clin Endocrinol (Oxf) 2009;71:154–5.10.1111/j.1365-2265.2008.03448.xSearch in Google Scholar PubMed
12. Kurnik D, Hochman I, Vesterman-Landes J, Kenig T, Katzir I, Lomnicky Y, et al. Muscle pain and serum creatine kinase are not associated with low serum 25(OH) vitamin D levels in patients receiving statins. Clin Endocrinol (Oxf) 2012; 77:36–41.10.1111/j.1365-2265.2011.04321.xSearch in Google Scholar
13. Needham M, Mastaglia FL. Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul Disord 2014;24:4–15.10.1016/j.nmd.2013.09.011Search in Google Scholar
14. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006;81:353–73.10.4065/81.3.353Search in Google Scholar
15. Smith NF, Figg WD, Sparreboom A. Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol 2005;1:429–45.10.1517/17425255.1.3.429Search in Google Scholar
16. Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 2001;276:35669–75.10.1074/jbc.M103792200Search in Google Scholar
17. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 2003;73:554–65.10.1016/S0009-9236(03)00060-2Search in Google Scholar
18. Group SC, Link E, Parish S, Armitage J, Bowman L, Heath S, et al. SLCO1B1 variants and statin-induced myopathy – a genomewide study. N Engl J Med 2008;359:789–99.10.1056/NEJMoa0801936Search in Google Scholar PubMed
19. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54:1609–16.10.1016/j.jacc.2009.04.053Search in Google Scholar PubMed PubMed Central
20. Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther 2012;92:112–7.10.1038/clpt.2012.57Search in Google Scholar PubMed PubMed Central
21. Hubáček JA, Dlouha D, Adamkova V, Zlatohlavek L, Viklicky O, Hruba P, et al. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population. Med Sci Monit 2015;21:1454–9.10.12659/MSM.893007Search in Google Scholar PubMed PubMed Central
22. Jiang J, Tang Q, Feng J, Dai R, Wang Y, Yang Y, et al. Association between SLCO1B1 -521T>C and -388A>G polymorphisms and risk of statin-induced adverse drug reactions: a meta-analysis. Springerplus 2016;5:1368.10.1186/s40064-016-2912-zSearch in Google Scholar PubMed PubMed Central
23. Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005; 15:97–8.10.1038/sj.cr.7310101Search in Google Scholar
24. Sole X, Guino E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics 2006;22:1928–9.10.1093/bioinformatics/btl268Search in Google Scholar PubMed
25. Alsuwadia AO, Farag YM, Al Sayyari AA, Mousa DH, Alhejaili FF, Al-Harbi AS, et al. Prevalence of vitamin D deficiency in Saudi adults. Saudi Med J 2013;34:814–8.Search in Google Scholar
26. Nair R, Maseeh A. Vitamin D: the “sunshine” vitamin. J Pharmacol Pharmacother 2012;3:118–26.Search in Google Scholar
27. Riche KD, Arnall J, Rieser K, East HE, Riche DM. Impact of vitamin D status on statin-induced myopathy. J Clin Transl Endocrinol 2016;6:56–9.10.1016/j.jcte.2016.11.002Search in Google Scholar PubMed PubMed Central
28. Shabana MF, Mishriki AA, Issac MS, Bakhoum SW. Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia. Mol Diagn Ther 2013;17:299–309.10.1007/s40291-013-0038-3Search in Google Scholar PubMed
29. Stewart A. SLCO1B1 polymorphisms and statin-induced myopathy. PLoS Curr 2013;5.10.1371/currents.eogt.d21e7f0c58463571bb0d9d3a19b82203Search in Google Scholar PubMed PubMed Central
30. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681–90.10.1001/jama.289.13.1681Search in Google Scholar PubMed
31. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 2006;130:1793–806.10.1053/j.gastro.2006.02.034Search in Google Scholar PubMed
32. Chung JY, Cho JY, Yu KS, Kim JR, Oh DS, Jung HR, et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 2005;78:342–50.10.1016/j.clpt.2005.07.003Search in Google Scholar PubMed
33. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. J Am Med Assoc 2003;289:1681–90.10.1001/jama.289.13.1681Search in Google Scholar
34. Gehani AA, Al-Hinai AT, Zubaid M, Almahmeed W, Hasani MR, Yusufali AH, et al. Association of risk factors with acute myocardial infarction in Middle Eastern countries: the INTERHEART Middle East study. Eur J Prev Cardiol 2014;21:400–10.10.1177/2047487312465525Search in Google Scholar PubMed
35. Zubaid M, Rashed WA, Almahmeed W, Al-Lawati J, Sulaiman K, Al-Motarreb A, et al. Management and outcomes of Middle Eastern patients admitted with acute coronary syndromes in the Gulf Registry of Acute Coronary Events (Gulf RACE). Acta Cardiol 2009;64:439–46.10.2143/AC.64.4.2041607Search in Google Scholar PubMed
36. Dai R, Feng J, Wang Y, Yang Y, Deng C, Tang X, et al. Association between SLCO1B1 521 TC and 388 AG polymorphisms and statins effectiveness: a meta-analysis. J Atheroscler Thromb 2015;22:796–815.10.5551/jat.26856Search in Google Scholar PubMed
37. Kanan RM, Al Saleh YM, Fakhoury HM, Adham M, Aljaser S, Tamimi W. Year-round vitamin D deficiency among Saudi female out-patients. Public Health Nutr 2013;16:544–8.10.1017/S1368980012002947Search in Google Scholar PubMed
38. Alfawaz H, Tamim H, Alharbi S, Aljaser S, Tamimi W. Vitamin D status among patients visiting a tertiary care center in Riyadh, Saudi Arabia: a retrospective review of 3475 cases. BMC Public Health 2014;14:159.10.1186/1471-2458-14-159Search in Google Scholar PubMed PubMed Central
39. Tuffaha M, El Bcheraoui C, Daoud F, Al Hussaini HA, Alamri F, Al Saeedi M, et al. Deficiencies under plenty of sun: vitamin D status among adults in the Kingdom of Saudi Arabia, 2013. N Am J Med Sci 2015;7:467–75.10.4103/1947-2714.168675Search in Google Scholar PubMed PubMed Central
40. Al-Daghri NM, Al-Attas OS, Alokail MS, Alkharfy KM, El-Kholie E, Yousef M, et al. Increased vitamin D supplementation recommended during summer season in the gulf region: a counterintuitive seasonal effect in vitamin D levels in adult, overweight and obese Middle Eastern residents. Clin Endocrinol (Oxf) 2012;76:346–50.10.1111/j.1365-2265.2011.04219.xSearch in Google Scholar PubMed
©2018 Walter de Gruyter GmbH, Berlin/Boston
